Skip to content
AnalystLens

Halozyme Therapeutics Quarterly Report for Q2 Ended Jun 30, 2026

Filing Date
Filed August 6, 2026
Period End
June 30, 2026
Security
HALO
One revenue dollarkept$0.48
In the record · 2016–202610-K1110-Q338-K141

HALO filed 11 annual reports (10-K), 33 quarterly reports (10-Q) and 141 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Jul ’17Jul ’17
  2. Leadership change8-K · Feb ’20Feb ’20
  3. Deal closed8-K · May ’22May ’22
  4. Leadership change8-K · Oct ’25Oct ’25

Summary

Summary of the 10-Q filed August 6, 2026. Cited figures are marked; the original filing is the authoritative source.

Halozyme Therapeutics, Inc. reported a strong second quarter of 2026, with total revenues of $481.0 milliona versus $325.7 million in the prior-year quarter, and net income of $229.9 million, or $1.90 per diluted share, compared with $165.2 million, or $1.33 per diluted share, a year earlier.

Royalties of $307.7 millionb rose from $205.6 million, driven by sales uptake of ENHANZE partner products such as VYVGART Hytrulo and DARZALEX SC. Product sales, net increased to $129.6 million, led by bulk rHuPH20 sales of $59.6 million, and revenues under collaborative agreements were $43.7 million, including $35.5 million of upfront license and target nomination fees. Operating income rose to $287.7 million from $202.4 million, although amortization of intangibles, research and development, and SG&A expenses all increased, partly reflecting the Elektrofi and Surf Bio acquisitions completed in late 2025.

Capital allocation was a major focus during the quarter. The company repurchased 4.8 million shares for $332.7 millionc in the second quarter, completed its February 2024 $750.0 million repurchase program in June 2026, and authorized a new program of up to $1.0 billion through December 31, 2028. Cash and cash equivalents were $163.1 million and marketable securities were $67.9 million at June 30, 2026, totaling $231.0 million.

Total long-term debt, net, plus the current portion stood at $2.15 billiond, consisting mainly of convertible notes, and the revolving credit facility of $750 million was undrawn. Management stated that existing cash, cash equivalents and marketable securities are sufficient to fund operations for at least the next 12 months. The filing also flags a risk tied to the Elektrofi acquisition: a partner is evaluating a potential return of a Hypercon target and will make a decision by February 2027.

If the partner returns the target without nominating an alternative with similar future cash flows, the company would need to evaluate its acquired customer relationship intangibles and goodwill, which could lead to a material interim impairment charge. The company also disclosed that it is not party to any legal proceedings expected to have a material adverse effect, while noting litigation costs in connection with a patent infringement case within SG&A.

Key Highlights

  1. Total revenues were $481.0 million in Q2 2026, up from $325.7 million in Q2 2025, and $857.7 million for the six months versus $590.6 million a year earlier.
  2. Royalties were $307.7 million in Q2 2026 versus $205.6 million, with VYVGART Hytrulo royalties of $72.6 million (up from $29.9 million) and DARZALEX royalties of $152.2 million (up from $120.0 million).
  3. Net income was $229.9 million in Q2 2026, or $1.90 per diluted share, compared with $165.2 million, or $1.33 per diluted share, in Q2 2025.
  4. Bulk rHuPH20 sales rose to $59.6 million in Q2 2026 from $23.3 million, and total product sales, net were $129.6 million versus $81.5 million.
  5. The company repurchased 4.8 million shares for $332.7 million in Q2 2026, completed the $750.0 million February 2024 program in June 2026, and authorized a new $1.0 billion program through December 31, 2028.
  6. Cash, cash equivalents and marketable securities totaled $231.0 million at June 30, 2026, against $2.15 billion in total carrying amount of long-term debt, and the $750 million revolving credit facility was undrawn.
  7. A potential partner return of a Hypercon target could trigger a material interim impairment charge to Elektrofi-related intangibles and/or goodwill, with a partner decision expected by February 2027.

Follow one dollar

Of each $1.00 of revenue in Q2 FY2026, Halozyme Therapeutics kept $0.48.

  1. Revenue$481.0M100.0%
  2. Cost of revenue−$79.2M16.5%
  3. Gross profit$401.8M83.5%
  4. Operating costs−$114.2M23.7%
  5. Operating income$287.7M59.8%
  6. Interest, other & tax−$57.7M12.0%
  7. Net income$229.9M47.8%
Computed from 10-QQ2 FY2026filed August 6, 2026Computed from this filing’s revenue, gross profit, operating income and net income · right columngrey figure: share of revenue

Financial Statements

Q2 FY2026 against Q2 FY2025

Line itemQ2 FY2026Q2 FY2025Change
Revenue$481.00M$325.72M+47.7%
Cost of Revenue$79.17M$46.36M+70.8%
Gross Profit$401.83M$279.36M+43.8%
R&D Expenses$27.66M$17.54M+57.7%
SG&A Expenses$57.00M$41.61M+37.0%
Operating Expenses$193.34M$123.28M+56.8%
Operating Income$287.65M$202.44M+42.1%
Net Income$229.91M$165.16M+39.2%
EPS (Basic)$1.96$1.36+44.1%
EPS (Diluted)$1.90$1.33+42.9%
Shares Outstanding (Basic)117.27M121.34M−3.4%
Shares Outstanding (Diluted)121.22M124.16M−2.4%

Frequently Asked Questions

  1. How did Halozyme's revenue and profitability change in the second quarter of 2026?

    Total revenues rose to $481.0 million from $325.7 million, and net income increased to $229.9 million from $165.2 million. Diluted EPS was $1.90 versus $1.33. Royalties were the main driver, increasing to $307.7 million from $205.6 million, while operating income rose to $287.7 million from $202.4 million.

  2. What drove the increase in royalty revenue?

    The filing attributes the increase primarily to continued sales uptake of ENHANZE partner products launched since 2020, predominantly VYVGART Hytrulo by argenx and DARZALEX SC by Janssen, along with contributions from other recently launched products. Earlier-launched products such as Herceptin and MabThera experienced modest price erosion.

  3. How much did Halozyme return to shareholders, and what is the remaining authorization?

    In the second quarter of 2026, Halozyme repurchased 4.8 million shares for $332.7 million at an average price of $69.30 per share. The new May 2026 program authorizes up to $1.0 billion of repurchases by December 31, 2028, with an expectation of buying back at least $400 million of shares in 2026. The filing shows approximately $824.9 million remaining under the programs as of June 30, 2026.

  4. What is the company's debt and liquidity position?

    Long-term debt, net was $1.94 billion, with a current portion of $209.0 million, mainly reflecting convertible notes due 2027, 2028, 2031 and 2032. The $750 million Amended Revolving Credit Facility was undrawn at June 30, 2026, and the company stated it was in compliance with all covenants. Management believes current cash, cash equivalents and marketable securities of $231.0 million will fund operations for at least the next 12 months.

  5. What are the main risks flagged in the filing?

    The filing highlights a possible material interim impairment of Elektrofi-related intangibles and/or goodwill if a partner returns a Hypercon target without an alternative of similar cash flows, with a decision expected by February 2027. It also updates risk factors on healthcare pricing pressures, including federal drug pricing initiatives such as the Inflation Reduction Act, state-level pricing legislation, and co-pay coupon program scrutiny.